LINC00507: A Drug Target / Disease Biomarker (G100862680)

Target Name: LINC00507

NCBI ID: G100862680

LINC00507

Other Name(s): Long intergenic non-protein coding RNA 507 | long intergenic non-protein coding RNA 507

LINC00507: A Drug Target / Disease Biomarker

LINC00507 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the myeloid-derived suppressor (MDS) gene, which is responsible for the development of a variety of hematological malignancies, including leukemia. MDS is a type of cancer that affects the bone marrow, where normal blood cells are produced. When MDS develops, it can give rise to a variety of serious and often fatal diseases, including acute myeloid leukemia, myelodysplastic syndromes, and myeloma.

LINC00507 is a non-coding RNA molecule that is produced by the myeloid-derived suppressor (MDS) gene. It is a key regulator of the MDS gene and has been shown to play a role in the development and progression of MDS. LINC00507 is expressed in a variety of tissues and cells, including the bone marrow, where it is known to regulate the production of MDS cells.

One of the most promising aspects of LINC00507 is its potential as a drug target. LINC00507 has been shown to interact with a variety of different molecules, including the protein PDGF-BB and the transcription factor NF-E2. These interactions suggest that LINC00507 may be a useful target for the development of cancer therapies.

In addition to its potential as a drug target, LINC00507 has also been identified as a potential biomarker for the diagnosis and prognosis of MDS. MDS is a type of cancer that affects the bone marrow and can give rise to a variety of serious and often fatal diseases, including acute myeloid leukemia, myelodysplastic syndromes, and myeloma. LINC00507 has been shown to be expressed in the blood and bone marrow of individuals with MDS, and studies have suggested that it may be a useful biomarker for the diagnosis and prognosis of MDS.

Overall, LINC00507 is a promising molecule for the development of cancer therapies and as a biomarker for the diagnosis and prognosis of MDS. Further research is needed to fully understand its potential and to develop effective treatments.

Protein Name: Long Intergenic Non-protein Coding RNA 507

The "LINC00507 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00507 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets